Onkologie. 2026:20(3):150-154 | DOI: 10.36290/xon.2026.028

From detection to destruction: a theranostic approach to prostate cancer

Veronika Ičová, Libuše Quinn, Lenka Henzlová, Milan Kamínek
Klinika nukleární medicíny, LF UP a FN Olomouc

Theranostics represents a concept wherein the same or similar targeting molecules are used both for diagnostic imaging and targeted radionuclide therapy. In prostate cancer, it involves the prostate-specific membrane antigen (PSMA) whose expression correlates with how aggressive and advanced the disease is. The article summarizes the current diagnostic options using positron emission tomography with prostate-specific membrane antigen ligands (PSMA PET/CT) labelled with the radionuclides 68Ga or 18F and radioligand therapy (RLT) using 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). Attention is also paid to perspective therapeutic options based on alpha emitters and novel radioligands that are currently the subject of intensive clinical research.

Keywords: theranostics, prostate cancer, PSMA PET/CT, 177Lu-PSMA-617.

Accepted: June 15, 2026; Published: July 1, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ičová V, Quinn L, Henzlová L, Kamínek M. From detection to destruction: a theranostic approach to prostate cancer. Onkologie. 2026;20(3):150-154. doi: 10.36290/xon.2026.028.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 1.7.2027

    References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322/caac.21660. Go to original source... Go to PubMed...
    2. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180-1192. doi: 10.1111/j.1742-1241.2011.02799.x. Go to original source... Go to PubMed...
    3. Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(9):1119-1134. doi: 10.1016/j.annonc.2020.06.011. Go to original source...
    4. Lecouvet FE, Talbot JN, Messiou C, et al. Monitoring the response of bone metastases to treatment with MRI and nuclear medicine techniques. Eur Radiol. 2014;24(4):843-853. doi: 10.1007/s00330-013-3072-3. Go to original source...
    5. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81-85.
    6. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer (proPSMA). Lancet. 2020;395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7. Go to original source... Go to PubMed...
    7. Česká onkologická společnost ČLS JEP. Doporučené postupy diagnostiky a léčby karcinomu prostaty. Aktualizace 2023. Available from: https://www.linkos.cz/.
    8. Eiber M, Fendler WP, Rowe SP, et al. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J Nucl Med. 2017;58(Suppl 2):67S-76S. doi: 10.2967/jnumed.116.186767. Go to original source... Go to PubMed...
    9. Hofman MS, Emmett L, Sandhu S, et al. [<sup>1</sup>⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in mCRPC (TheraP). Lancet. 2021;397(10276):797-804. doi: 10.1016/S0140-6736(21)00236-3. Go to original source...
    10. Lin Y, Gao H, Xie Y, et al. [18F]FDG and [68Ga]Ga-PSMA dual-tracer total-body PET/CT and PET/MR in patients with prostate cancer. Q J Nucl Med Mol Imaging. 2025;69(2):146-156. doi: 10.23736/S1824-4785.25.03637-4. Go to original source... Go to PubMed...
    11. Shen Z, Li Z, Li Y. PSMA PET/CT for prostate cancer diagnosis: current applications and future directions. J Cancer Res Clin Oncol. 2025;151(5):155. doi: 10.1007/s00432-025-06184-z. Go to original source... Go to PubMed...
    12. De Man K, Van Laeken N, Schelfhout V, et al. 18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial. Eur Urol. 2022;82(5):501-509. doi: 10.1016/j.eururo.2022.05.010. Go to original source... Go to PubMed...
    13. Zlatopolskiy BD, Endepols H, Krapf P, et al. Discovery of 18F-JK-PSMA-7, a PET Probe for the Detection of Small PSMA-Positive Lesions. J Nucl Med. 2019;60(6):817-823. doi: 10.2967/jnumed.118.218495. Go to original source...
    14. Hoberück S, Löck S, Borkowetz A, et al. Intraindividual comparison of [68Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Res. 2021;11(1):109. doi: 10.1186/s13550-021-00845-z. Go to original source... Go to PubMed...
    15. Huang S, Ong S, McKenzie D, et al. Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024;27(4):654-664. doi: 10.1038/s41391-023-00755-2. Go to original source... Go to PubMed...
    16. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic Efficacy of (68)Gallium-PSMA PET Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016;195(5):1436-1443. doi: 10.1016/j.juro.2015.12.025. Go to original source... Go to PubMed...
    17. Mookerji N, Pfanner T, Hui A, et al. Fluorine-18 PSMA-1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer. JAMA Oncol. 2024;10(8):1097-1103. doi: 10.1001/jamaoncol.2024.3196. Go to original source...
    18. Soeterik TFW, Heetman JG, Hermsen R, et al. The Added Value of PSMA PET/CT to MRI for Local Staging of Prostate Cancer in Patients Undergoing Radical Prostatectomy. Eur Urol Oncol. 2025;8(3):731-738. doi: 10.1016/j.euo.2024.11.002. Go to original source... Go to PubMed...
    19. Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Prostate Cancer Recurrence: A Prospective Multicenter Clinical Trial. JAMA Oncol. 2019;5(6):845-851. doi: 10.1001/jamaoncol.2019.0096. Go to original source...
    20. Han S, Woo S, Kim YJ, et al. Impact of 68Ga-PSMA PET/CT on Management of Prostate Cancer Patients with Biochemical Recurrence: A Systematic Review and Meta-Analysis. Eur Urol. 2020;78(2):179-188. doi: 10.1016/j.eururo.2020.03.045. Go to original source... Go to PubMed...
    21. Liu C, Liu T, Zhang Z, et al. 68Ga-PSMA PET/CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer. J Nucl Med. 2020;61(9):1314-1319. doi: 10.2967/jnumed.119.235333. Go to original source... Go to PubMed...
    22. Zhang LL, Li WC, Xu Z, et al. 68Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy. Eur J Nucl Med Mol Imaging. 2021;48(2):483-492. doi: 10.1007/s00259-020-04863-2. Go to original source... Go to PubMed...
    23. Peng J, Jin J, Gao H, et al. PSMA PET versus 99mTc-MDP bone scan for diagnosing bone metastasis in prostate cancer: a head-to-head comparative meta-analysis. Front Med (Lausanne). 2024;11:1451565. doi: 10.3389/fmed.2024.1451565. Go to original source... Go to PubMed...
    24. Sandhu S, Guo C, Hofman MS. Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics. J Nucl Med. 2021;62(12):1660-1668. doi: 10.2967/jnumed.120.243295. Go to original source...
    25. Shah H, Ravi P, Sonpavde G, et al. Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2022;22(11):1163-1175. doi: 10.1080/14737140.2022.2139679. Go to original source... Go to PubMed...
    26. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Go to original source... Go to PubMed...
    27. Yazdanpanah O, Calais J, Chi KN, et al. Efficacy of 177Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis. J Clin Oncol. 2025;43(4_suppl):121-121. doi: 10.1200/JCO.2025.43.4_suppl.121. Go to original source...
    28. Hofman MS, Violet J, Hicks RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial). Lancet Oncol. 2018;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Go to original source... Go to PubMed...
    29. Morris MJ, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of ARPI therapy for taxane-naive patients with progressive mCRPC (PSMAfore). Lancet. 2024;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Go to original source...
    30. Hofman MS, Emmett L, Sandhu S, et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in mCRPC (TheraP). Lancet Oncol. 2024;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6. Go to original source... Go to PubMed...
    31. Curium. Curium Announces ECLIPSE Trial Has Met Primary Endpoint [online]. London: Curium Pharma; 2024 Oct 15 [cit. 2026-01-28]. Available from: https://www.curiumpharma.com/2024/10/15/curium-announces-eclipse-trial-primary-endpoint-met/.
    32. Bundy PJ, Pook D, Lawrentschuk N, et al. ProstACT GLOBAL: A phase 3 study of 177Lu-DOTA-rosopatamab (TLX591). J Clin Oncol [online]. 2024 [cit. 2026-01-28];42(4_suppl):TPS265. Available from: https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.TPS265.
    33. Morris MJ, George DJ, Tagawa ST, et al. CONVERGE-01: Dosimetry and efficacy of ac-225 rosopatamab tetmorraxetan. J Clin Oncol [online]. 2025 [cit. 2026-01-28];43(5_suppl): TPS289. Available from: https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.TPS289. Go to original source...
    34. Deshayes E, Fersing C, Thibault C, et al. Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers. Cancers (Basel). 2023;15(12):3133. doi: 10.3390/cancers15123133. Go to original source...
    35. Ma J, Li L, Liao T, et al. Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in mCRPC: A Systematic Review and Meta-Analysis. Front Oncol. 2022;12:796657. doi: 10.3389/fonc.2022.796657. Go to original source... Go to PubMed...
    36. Sathekge MM, Lawal IO, Bal C, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act). Lancet Oncol. 2024;25(2):175-183. doi: 10.1016/S1470-2045(23)00638-1. Go to original source...
    37. Novartis Pharmaceuticals. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (AcTFirst) [online]. ClinicalTrials.gov ID: NCT06855277. [cit. 2026-01-28]. Available from: https://clinicaltrials.gov/study/NCT06855277.
    38. Novartis Pharmaceuticals. Open-label Study Comparing AAA817 Versus Standard of Care (AcTSecond) [online]. ClinicalTrials.gov ID: NCT06780670. [cit. 2026-01-28]. Available from: https://clinicaltrials.gov/study/NCT06780670.
    39. Tagawa ST, Thomas C, Viray H, et al. Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591. Cancer Res [online]. 2024 [cit. 2026-01-28];84(7_suppl):CT014. Available from: https://aacrjournals.org/.
    40. Tagawa ST. ESMO 2025: Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). UroToday [Online]. 2025 Oct 14. Available from: https://www.urotoday.com/conference-highlights/esmo-2025/esmo-2025-prostate-cancer/164097-esmo-2025-phase-iii-trial-of-177lu-lu-psma-617-combined-with-adt-arpi-in-patients-with-psma-positive-metastatic-hormone-sensitive-prostate-cancer-psmaddition.html. Go to original source...
    41. University College London. STAMPEDE2: A Randomised Controlled Platform Trial Testing Treatments in mHSPC [online]. ClinicalTrials.gov ID: NCT06320067. [cit. 2026-01-28]. Available from: https://clinicaltrials.gov/study/NCT06320067.
    42. Liu Y, Watabe T, Kaneda-Nakashima K, et al. Fibroblast activation protein targeting radiopharmaceuticals. Antiviral Res. 2021;193:105116. doi: 10.1016/j.antiviral.2021.105116. Go to original source... Go to PubMed...
    43. Scott AM, Zeglis BM, Lapi SE, et al. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology. Lancet Oncol. 2024;25(6):e250-e259. doi: 10.1016/S1470-2045(24)00037-8. Go to original source...
    44. Abdel-Wahab M, Giammarile F, Carrara M, et al. Radiotherapy and theranostics: a Lancet Oncology Commission. Lancet Oncol. 2024;25(11):e545-e580. doi: 10.1016/S1470-2045(24)00407-8. Go to original source... Go to PubMed...
    45. Baum RP, Kulkarni HR. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy. Theranostics. 2012;2(5):437-447. doi: 10.7150/thno.3645. Go to original source... Go to PubMed...
    46. Kind F, Michalski K, Yousefzadeh-Nowshahr E, et al. Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progres­sion? EJNMMI Res. 2022;12(1):20. doi: 10.1186/s13550-022-00891-1. Go to original source... Go to PubMed...
    47. Strosberg JR, Caplin ME, Kunz PL, et al. 177Lu-Dotatate versus high-dose octreotide in midgut neuroendocrine tumours (NETTER-1). Lancet Oncol. 2021;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.